In this Q&A, Mark Freitas, managing director and life sciences practice lead at Alvarez & Marsal, discusses how clinical ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
Incyte has reported final 24-week data from the Phase III TRuE-AD4 study. The results show sustained efficacy along with a consistent safety profile for Opzelura (ruxolitinib) cream in adults with ...
LUCENT-3 trial open-label extension data show 63.5% of adults with ulcerative colitis administered mirikizumab (Omvoh) who ...
TransCelerate BioPharma has released a summary report from a joint tabletop exercise conducted with the FDA's Center for Drug ...
A phase 3 trial evaluating Moderna’s investigational seasonal influenza vaccine, mRNA-1010, found the messenger RNA ...
FDA-regulator access to near real-time safety and endpoint streams is intended to enable earlier signal detection and more ...
Guselkumab (Tremfya) showed higher 24-week fistula remission than placebo in adults with perianal fistulizing Crohn disease.
As the use of digital tools continues to expand within clinical research, effective data management for eCOA systems is more important than ever. From initial design and system setup to ongoing ...
Execution instability often originates in strategy timing rather than study conduct, which sponsors can correct by ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
In a recent video interview with Applied Clinical Trials, Hal Green, senior solution architect and life sciences vertical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results